FDA Approves Brain Tumor Treatment by Drugmaker Servier

An undated file photo shows computer-enhanced, false-color magnetic resonance images (MRI) of brain structures. Alfred Pasieka/Science Photo Library/Getty Images

The U.S. Food and Drug Administration (FDA) has approved Voranigo, a new drug from the French pharmaceutical firm Servier, for the treatment of a type of brain cancer.

It is the first treatment in the United States to be approved by the FDA for treating a form of brain cancer, called Grade 2 IDH-mutant glioma, in patients who have had surgery.